We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.
Management gave specific numerical guidance and timelines: OCU400 (Limelight) completed enrollment (n=140, randomized 2:1), uses a one‑year primary LDNA endpoint (clinically meaningful ≥1 lux), is on track to begin a rolling BLA in 2026 (Q3 cited), with top‑line data and potential approval/commercialization in 2027; OCU410 (GA) released preliminary 12‑month Phase 2 data showing a 46% lesion‑growth reduction versus control (p=0.015, cohort n=23), a 50% responder rate (>50% lesion reduction), subgroup ≥7.5 mm² with 56–57% reductions, and a Phase‑1 observation of 60% slower EZ loss, with full Phase 2 data due this month and Phase 3 planned in 2026; OCU410ST (Stargardt) is ahead of schedule with enrollment expected complete in early‑2026, an adaptive masked interim analysis of 24 subjects (16 treatment/8 control) planned in Q3 and top‑line Phase 2/3 data and a BLA path targeted in 2027, with EZ exploratory results showing ~16% lesion reduction and 50% of treated eyes achieving EZ preservation at 12 months; other programs: OCU200 enrollment expected complete in 2026 and OCU500 Phase‑1 initiation by NIAID in 2026; and financial guidance: FY2025 R&D $39.8M (Q4 $10.7M), G&A $27.6M (Q4 $6.1M), FY2025 net loss per share $0.23 (Q4 $0.06), cash runway into 2026 supported by a $22.5M registered direct raise and a potential extension into 2027 if $30M of warrants are fully exercised, with management reiterating a plan to file three BLAs in the next three years.
Limelight Phase 3 enrollment complete with 140 patients randomized 2:1 (treatment:control); gene-agnostic design covering major mutations (e.g., USH2A, XLRP, PDE6B). Top-line one‑year data expected in 2027, rolling BLA submission planned to begin in 2026 and potential commercialization targeted in 2027.
Positive three‑year Phase 1/2 data show sustained, clinically meaningful approximately two-line LLVA gain and durable, favorable safety/tolerability with no new treatment‑related serious adverse events reported.
Preliminary 12‑month data (≈50% of patients evaluated; n cohort cited = 23) show a 46% reduction in lesion growth across combined medium/high doses versus control (p = 0.015). Observed 50% responder rate (>50% lesion size reduction vs control). Subgroup with baseline lesion ≥7.5 mm² showed 57% (medium) and 56% (high) reduction versus control. Phase 3 planned to initiate in 2026.
Phase 1 findings reported a 60% slower ellipsoid zone (EZ) loss rate in treated eyes versus untreated fellow eyes, indicating substantial slowing of photoreceptor degeneration; EZ included as key exploratory/structural endpoint across trials.
Phase 2/3 Guardian‑3 pivotal trial remains ahead of schedule with top-line data anticipated in 2027. Peer‑reviewed Phase 1 Guardian results published in Nature Eye supporting favorable safety, tolerability, and efficacy. Interim EZ structural analysis showed approximately 16% lesion reduction at 12 months and 50% of treated eyes achieved EZ preservation exceeding expected decline.
CHMP/EMA confirmed U.S.-based trial data can support EMA application for OCU410ST, enabling timeline and budget efficiencies across U.S. and Europe development plans.
Executed first regional licensing agreement for OCU400 (exclusive Korea rights with upfront, milestone payments and royalties), enabling near‑term value capture while preserving U.S./European rights. Strategy aims to maximize global patient reach while retaining core geographies.
Raised $22.5M via an underwritten registered direct offering led by RTW Investments. Company notes current cash and cash equivalents extend runway into 2026; potential exercise of $30.0M in existing warrants could extend runway into 2027.
Key senior hires to support commercialization and operations: Abhi Gupta (EVP, Commercial & BD), Rita Johnson Green named CFO, and Paul Halsted (EVP, Operations) with significant biologics and gene therapy manufacturing experience.
Portfolio progress includes OCU200 with no reported SAEs (enrollment expected complete in 2026), OCU500 enhanced vaccine Phase 1 intended to be initiated by NIAID in 2026, and Rare Pediatric Disease designation for OCU410ST; company created Arthroselix subsidiary to unlock regenerative assets value.
Good morning, and welcome to Ocugen, Inc.'s Fourth Quarter and Full Year 2025 Financial Results and Business Update. All participant lines are currently in listen-only mode. Following the speakers' commentary, there will be a question-and-answer session. I will now turn the call over to Tiffany Hamilton, Ocugen, Inc.'s Head of Corporate Communications. You may begin.
Thank you, Operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen, Inc.'s Chairman, CEO, and Co-Founder, who will provide a business update and an overview of our clinical and operational progress. Rita Johnson Green, our Chief Financial Officer, is also on the call to provide a financial update for the quarter and full year ended 12/31/2025. Dr. Huma Qamar, Chief Medical Officer, will be available to answer questions following the presentation. This morning, we issued a press release detailing associated business and operational highlights for the fourth quarter and full year 2025. We encourage listeners to review the press release, which is available on our website at ocugen.com.
A replay of this call, along with the accompanying slide presentation, will be available on the Investors section of the Ocugen, Inc. website at investors.ocugen.com. Before we begin, please note that certain statements made during today's discussion may be forward-looking in nature, including those related to our clinical development pipeline, regulatory timelines, commercialization strategy, and financial information and our anticipated cash runway. These statements reflect mana...